JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M206040200 on September 16, 2002

J. Biol. Chem., Vol. 277, Issue 47, 45638-45643, November 22, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/47/45638    most recent
M206040200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, H.-F.
Right arrow Articles by Harris, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, H.-F.
Right arrow Articles by Harris, R. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cyclooxygenase-2 Expression in Cultured Cortical Thick Ascending Limb of Henle Increases in Response to Decreased Extracellular Ionic Content by Both Transcriptional and Post-transcriptional Mechanisms

ROLE OF p38-MEDIATED PATHWAYS*

Hui-Fang Cheng and Raymond C. HarrisDagger

From the George M. O'Brien Kidney and Urologic Diseases Center and Division of Nephrology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Received for publication, June 18, 2002, and in revised form, August 14, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We showed previously that decreased extracellular salt or chloride up-regulates the cortical thick ascending limb of Henle (cTALH) COX-2 expression via a p38-dependent pathway. The present studies determined that low salt medium increased COX-2 mRNA expression 3.9-fold control by 6 h in cultured cTALH, which was blocked by actinomycin D pretreatment, suggesting transcriptional regulation. Luciferase activity (normalized to beta -galactosidase activity) of the full-length (-3400) COX-2 promoter in cTALH increased from 1.8 ± 0.3 in control media to 5.8 ± 0.7 in low salt (n = 9; p < 0.01). Low chloride medium had similar effects as low salt has on COX-2 promoter activity. Deletion constructs -815, -512, and -410 were similarly stimulated, but -385 could not be stimulated significantly by low salt (1.8 ± 0.3 versus 2.4 ± 0.5, n = 10). This suggested involvement of an NF-kappa B cis-element located in this region, which was confirmed by utilizing a construct with a point mutation of this NF-kappa B-binding site that was not stimulated by low salt medium. Co-incubation of the specific p38 inhibitor, SB203580 or PD169316, inhibited a low salt-induced increase in luciferase activity of the intact COX-2 promoter (5.8 ± 0.7 versus 1.1 ± 0.2, n = 8 and 1.4 ± 0.4, n = 4 respectively, p < 0.01). Mobility shift assays indicated that the low salt medium stimulated NF-kappa B binding activity, and this stimulation was inhibited by p38 inhibitors. To test whether p38 also increased COX-2 expression by increasing mRNA stability, cTALH were incubated in low salt for 2 h, and actinomycin was then added with or without SB203580. p38 inhibition led to a decreased half-life of COX-2 mRNA (from 68 to 18 min, n = 4-7, p < 0.05). Therefore, these studies indicate that p38 stimulates COX-2 expression in cTALH and macula densa by transcriptional regulation predominantly via a NF-kappa B-dependent pathway and by post-transcriptional increases in mRNA stability.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Prostaglandins are metabolized from arachidonic acid through cyclooxygenase (COX)-dependent1 pathways (1) and modulate vascular tone, expression and secretion of renin, and salt and water homeostasis in the mammalian kidney. Two isoforms of COX have been found: COX-1, which is constitutive, and COX-2, which is inflammation-mediated and glucocorticoid-sensitive (2-4). We originally reported that salt restriction increases renal cortical COX-2 expression selectively in tubular epithelial cells of macula densa and the surrounding cortical thick ascending limb of Henle (cTALH) (5), which was confirmed by subsequent studies (6). The macula densa is recognized to be important for regulation of renal renin expression and regulation of afferent renal arteriolar tone through the process of tubuloglomerular feedback (7). Up-regulation of COX-2 in these cells was also found in other high renin states, such as angiotensin-converting enzyme inhibitor (8, 9), diuretic administration (10), and experimental renovascular hypertension (11).

We previously demonstrated that COX-2 is an important mediator for renin release from macula densa (8, 12). It has been suggested that decreased intraluminal chloride concentration is the signal for macula densa stimulation of renin secretion (13, 14). Ion substitution experiments in perfusion of isolated cortical thick ascending limbs with associated juxtaglomerular apparati indicated that only when chloride was replaced by alternative anions was renin secretion increased; no increase in renin expression or secretion could be seen in response to sodium substitution by other cations (15). Our previous studies indicated that decreased extracellular NaCl or selective decreases in extracellular chloride up-regulated cTALH COX-2 expression, and this up-regulation of COX-2 in cTALH occurred via a p38-dependent pathway (16). The current study investigated the transcriptional and post-transcriptional regulation of COX-2 by alteration of extracellular salt or chloride.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Goat anti-human uromucoid antibody was from ICN (Costa Mesa, CA). Anti-goat IgG (H+L) was from Vector Laboratory (Burlingame, CA). Anti-p65, -p50, -p52, and -c-Rel antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Rat COX-2 cDNA was from Oxford Biomedical Research (Oxford, MI). The luciferase assay system and gel shift assay systems were from Promega (Madison, WI). SB203580, PD169316, and Bay 11-7082 were from Calbiochem Bioscience Inc. (La Jolla, CA). [32P]CTP (3,000 Ci/mmol) and [gamma -32P]ATP (3,000 Ci/mmol at 10 mCi/ml) were from PerkinElmer Life Sciences. LipofectAMINE was from Invitrogen. Other reagents were purchased from Sigma.

Primary Culture of Rabbit cTALH Cells-- cTALH cells were isolated from homogenates of rabbit renal cortex by immunodissection with anti-Tamm Horsfall antibody, as previously described (8, 17, 18). Briefly, the renal cortex was dissected, minced, and digested with 0.1% collagenase. After blocking with 10% bovine serum albumin, the sieved homogenates were incubated with goat anti-human Tamm Horsfall antiserum (50 mg/ml) for 30 min on ice, followed by washing and addition to plastic Petri dishes coated with anti-goat IgG (8 mg/ml). Attached cells resistant to washing were dislodged and grown to confluence in Dulbecco's modified Eagle' medium/Ham's F-12 medium with 10% fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C in 95% air, 5% CO2.

Plasmid Constructs and Mutagenesis-- The proximal 3.2 kb of the mouse COX-2 promoter was cloned by reverse transcription-PCR from mouse kidney RNA with the 5' primer (CAT GAA TTC TGT TCT GCC CTC ATG TGT ATG) and the 3' primer (TAA GGT ACC GGT GGA GCT GGC AGG ATG CAG TGC A) and then subcloned into a luciferase reporter vector (Promega). The -815 and -512 deletion luciferase reporter constructs were a generous gift from Dr. Yamamoto (19). The mouse COX-2 promoter was cut with EcoRI and PpuMI, blunted, and self-ligated to make the -385 deletion construct. The XhoI cutting site was introduced by point mutation to produce the -410 deletion construct. NF-kappa B and CREB point mutants were also constructed (Stratagene, La Jolla, CA). Briefly, the luciferase reporter plasmid containing the mutation for NF-kappa B or CREB was developed. After PCR amplification, the product was treated with endonuclease DpnI and then transformed to XL 1-Blue supercompetent cells. All of the mutants and other plasmid constructs were verified by sequencing.

Transfection and Luciferase Reporter Assay-- Primary cultured cTALH cells at 50-60% confluence were transiently transfected with LipofectAMINE reagent (Invitrogen). When the cells grew to confluence (48 h later), they were made quiescent with serum-free medium for 16 h and then changed to the indicated condition (e.g. low salt or low chloride medium) for 6 h. The content of low salt or low chloride medium was as previously described (16). The cells were extracted with lysis buffer (luciferase assay system; Promega), and their luciferase activities were measured with a LumiCount Microplate Luminometer (model AL10000; Packard Bioscience Co., Meridian, CT). The results were normalized to beta -galactosidase activity as previously described (20).

RNA Extraction and Northern Blotting-- Primary cultured cTALH cell RNA was extracted by the acid guanidium thiocyanate-phenol chloroform method (21). RNA samples were electrophoresed in denatured agarose gel, transferred to nitrocellulose membranes, and hybridized with a 32P-labeled cDNA of rat COX-2. The membranes were then stripped and rehybridized with glyceraldehyde-3-phosphate dehydrogenase.

Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)-- Nuclear protein was extracted as previously described (22, 23). Briefly, the cells were homogenized with a Dounce homogenizer in buffer containing 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 0.1% leupeptin. 10% Nonidet P-40 was added to make a final concentration of 0.5%, incubated on ice for 30 min, and centrifuged. After washing, the pellet was resuspended in 20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, I mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, and 0.1% leupeptin with 1/10 volume of 4 M KCl. EMSA was performed as described (24). Double-stranded NF-kappa B and CREB oligonucleotides were end-labeled with [32P]ATP by T4 polynucleotide kinase. 5 µg of nuclear protein was added to the reaction mixture, incubated for 30 min at 25 °C, and resolved on 6% nondenatured polyacrylamide gels. Antibody supershift EMSA was performed by incubating nuclear extracts with anti-p65, -p50, -p52, or -c-Rel antibody or irrelevant control antibody for 10 min at room temperature before adding the labeled probe.

Immunoblotting-- Renal cortices were homogenized with RIPA buffer and centrifuged, heated to 100 °C for 5 min with sample buffer, separated on SDS gels under reducing conditions, and transferred to Immobilon-P transfer membranes (Millipore, Bedford, MA). The blots were blocked overnight with 100 mM Tris-HCl, pH 7.4, containing 5% nonfat dry milk, 3% albumin, and 0.5% Tween 20, followed by incubation for 16 h with monoclonal Ikappa B or pIkappa B antibodies. The second biotinylated antibody reagent was detected using avidin and biotinylated horseradish peroxidase (Pierce) and exposed on film using ECL (Amersham Biosciences).

Statistical Analysis-- All of the values are presented as the means ± S.E. Analysis of variance and Bonferroni t tests were used for statistical analysis, and the differences were considered significant when p < 0.05.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In previous studies we demonstrated that immunoreactive COX-2 protein increased in primary cultured cTALH in response to exposure to low salt or low chloride medium. Substitution of other cations for sodium did not affect COX-2 expression, whereas substitution of other anions for chloride led to increased COX-2 expression (16). In the present studies, we determined that COX-2 mRNA expression increased in low salt medium, with an apparent peaking within 6 h (3.9 ± 0.4-fold control) and increased expression observed for up to 16 h (3.4 ± 0.5-fold control) (Fig. 1A). When cells were preincubated with 5 µg/ml actinomycin D (25) for 20 min prior to exposure to low salt medium, increases in COX-2 mRNA expression were blocked (Fig. 1B). The time course of COX-2 mRNA increase and inhibition by actinomycin D were similar in low chloride medium (not shown).


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 1.   Actinomycin inhibits the transcription of COX-2 mRNA from cultured cTALH cells in low salt medium. Rabbit cTALH cells were isolated by immunodissection with anti-Tamm Horsfall antibody as described under "Experimental Procedures." After quiescence, the cells were incubated in low salt medium without (A) or with (B) 5 µg/ml actinomycin D. The cells were harvested at the indicated times, RNA was extracted, and mRNA expression was measured by Northern blotting. The Northern blot shown here is representative of five independent experiments.

Informative deletions of the murine COX-2 promoter were constructed (Fig. 2A) and transfected into cTALH cells. After quiescence, the cells were exposed to normal or low salt medium for 6 h, and luciferase activity was measured, normalized by beta -galactosidase activity, and expressed as fold control (Fig. 2B). Luciferase activity of the vector transfected cells was identical if grown in normal medium or low salt medium (1.2 ± 0.1-fold control, n = 14-18, NS). There were no significant differences of luciferase activity among the six groups when grown in normal medium. Low salt medium elevated the luciferase activity of full-length COX-2 promoter-transfected cells (5.2 ± 0.4-fold control, n = 10, p < 0.01). Low salt medium induced similar increases in promoter activity with the -815 construct (5.4 ± 0.6-fold control, n = 17-18, p < 0.01) and the -512 deletion construct (5.6 ± 0.5-fold control in low salt medium, n = 17-18, p < 0.01). However, there was no significant increase in luciferase activity by low salt medium in the -385 deletion construct (1.8 ± 0.2 in normal medium versus 2.4 ± 0.5-fold control in low salt medium, n = 10, NS). Of note, the murine COX-2 promoter contains putative CREB and NF-kappa B sites between -512 and -385. An additional deletion at -410 removed the putative CREB site but did not interrupt the NF-kappa B site. Fig. 2A indicated that the -410 deletion still responded to low salt stimulation (1.6 ± 0.2 in normal medium versus 5.5 ± 0.8-fold control in low salt medium, n = 8, p < 0.01). The NF-kappa B inhibitor, BAY 11-7082 (10 µM) (26) also inhibited the low salt medium-induced increase in luciferase activity in the -815 construct (to 2.7 ± 0.6-fold control, n = 8, p < 0.01) (Fig. 3).


View larger version (13K):
[in this window]
[in a new window]
  		Fig. 2.   Luciferase activity of COX-2 promoter stimulation by low salt. A, structure of murine COX-2 promoter gene. Indicated are the deletion constructs utilized in the studies. B, the -410 to -385 region is crucial for low salt-induced COX-2 promoter activity. Cultured cTALH cells were co-transfected with the indicated COX-2 promoter deletion plasmids and beta -galactosidase plasmids as described under "Experimental Procedures." The cells were cultured to confluence and incubated in normal growth medium without serum or low salt medium for 6 h. Luciferase activity was normalized to beta -galactosidase activity and expressed as fold control. **, p < 0.01.


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 3.   NF-kappa B and p38 inhibitors block low salt-induced COX-2 promoter activity. cTALH cells were transfected with the -815 COX-2 promoter construct in the absence or presence of the NF-kappa B inhibitor BAY11-7082 (10 µM) or the p38 inhibitors SB203580 (10 µM) or PD169316 (1 µM) (n = 8). **, p < 0.01. LS, low salt.

To confirm a role for the putative NF-kappa B site in low salt medium-induced increases in luciferase activity, inactive mutations of the indicated NF-kappa B and CREB sites were constructed (19) (Fig. 4A). The CREB mutant construct had a significant increase in luciferase activity in response to the low salt medium, although the stimulation was somewhat less than what was observed with the wild type construct. In contrast, the NF-kappa B mutation completely blocked low salt medium-induced activation (Fig. 4B). Similar responses were seen in the low chloride medium (-815 deletion, from 1.7 ± 0.2- to 4.6 ± 1.0-fold control, n = 4, p < 0.01; NF-kappa B mutation, from 1.2 ± 0.1- to 1.3 ± 0.3-fold control, n = 4, NS). (Fig. 4C).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 4.   The NF-kappa B binding site at -390 to -399 is necessary for low salt or low chloride-induced COX-2 promoter activity. A, COX-2 promoter mutations of the -815 to NF-kappa B and -815 to CREB binding sites at -432 to -427. B, effect of low salt. **, p < 0.01. C, effect of low chloride. **, p < 0.01.

In EMSA of cTALH nuclear extracts incubated with a consensus NF-kappa B oligonucleotide, two specific bands were detected (Fig. 5A). Low salt medium incubation stimulated the NF-kappa B binding activity (Fig. 5B). CREB binding by nuclear extracts from cTALH cells exposed to low salt medium was also slightly decreased compared with control (Fig. 5C). Supershift assay indicated that the two bands seen in the NF-kappa B EMSAs were p65 and p50 (Fig. 5D).


View larger version (45K):
[in this window]
[in a new window]
  		Fig. 5.   EMSA in cTALH cells exposed to low salt medium. A, NF-kappa B EMSA. Gel shift assays with NF-kappa B probes were performed as described under "Experimental Procedures." Lane 1, negative control without nuclear extract; lanes 2-4, EMSA with nuclear extract from cTALH cells grown in normal growth medium; lane 5, specific competition with unlabeled NF-kappa B oligonucleotide; lane 6, nonspecific competition with unlabeled noncompetitor AP1 consensus oligonucleotide. B, low salt increases NF-kappa B binding, which is inhibited by the p38 inhibitor, SB203580. Lane 1, free probe only; lane 2, nuclear extracts of cTALH cells in normal growth medium; lane 3, low salt medium; lane 4, low salt medium combined + SB203580 (10 µM). C, low salt has less effect on CREB binding. Lane 1, free probe; lane 2, cTALH cells in normal growth medium; lane 3, low salt; lane 4, low salt + SB203580; lane 5, competition with unlabeled CREB oligonucleotide; lane 6, nonspecific competition with unlabeled noncompetitor AP1 consensus oligonucleotide. D, supershift assay of NF-kappa B binding. Lane 1, negative control without nuclear extract; lane 2, rabbit IgG; lane 3, NF-kappa B p65-specific antibody; lane 4, NF-kappa B p50-specific antibody; lane 5, simultaneous addition of p65 and p50 antibodies; lane 6, c-Rel antibody.

Because activation of cytoplasmic NF-kappa B and translocation to the nucleus is regulated by phosphorylation of Ikappa B, we determined Ikappa B and pIkappa B expression in cTALH cells. Low salt medium decreased Ikappa B expression (0.4 ± 0.1-fold control, n = 7, p < 0.01) (Fig. 6A) and increased immunoreactive pIkappa B expression (2.2 ± 0.2-fold control, n = 8, p < 0.05) (Fig. 6B).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of low salt medium on Ikappa B in cTALH cells. A, immunoreactive Ikappa B (ir-ikappa B) expression of cTALH cells decreases in low salt medium. The cells were treated as described in the legend to Fig. 2. Immunoreactive Ikappa B expression was measured by Western blotting (n = 7). **, p < 0.01. B, low salt increases immunoreactive pIkappa B expression (n = 8). **, p < 0.01.

When a p38-specific inhibitor, PD169316 (1 µM) (16) or SB 203580 (10 µM) (27), was added to low salt or low chloride medium, stimulation of luciferase activity in the -815 construct was decreased (PD169316, from 5.4 ± 0.3- to 1.4 ± 0.4-fold control, n = 6, p < 0.01; SB203580, 1.1 ± 0.2-fold control, n = 8, p < 0.05) (Fig. 3). EMSA further confirmed that SB203580 reduced the increases in NF-kappa B binding ability (Fig. 5B). SB203580 also inhibited increases in Ikappa B phosphorylation stimulated by low salt (1.4 ± 0.1 of control medium, n = 8, NS) and prevented decreases in Ikappa B levels (0.9 ± 0.1, n = 7, NS) (Fig. 6).

In other cell systems, alterations in COX-2 mRNA expression have been attributed to both transcriptional and post-transcriptional regulation. To test the possibility that there was a component of post-transcriptional stabilization of COX-2 mRNA in response to low salt or low chloride medium, cTALH cells were stimulated by low salt medium for 2 h, and then actinomycin D was added with or without the specific p38 inhibitor, SB203580. p38 inhibition led to an increased decay rate of COX-2 mRNA (from 68 to 18 min, n = 4-7, p < 0.05) (Fig. 7), suggesting that p38 activity may also regulate COX-2 mRNA stability with low salt stimulation.


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 7.   p38-mediated COX-2 mRNA stabilization in low salt medium. Primary cultured cTALH cells were exposed to low salt medium for 2 h, and then actinomycin (5 µg/ml) was added, with or without SB203580 (10 µM). The time course of COX-2 mRNA expression was measured by Northern blotting, normalized to glyceraldehyde-3-phosphate dehydrogenase, and expressed as fold control. *, p < 0.05.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In vivo, dietary salt restriction increases COX-2 expression in the macula densa and the surrounding cTALH cells (5, 6). Macula densa/cTALH regulate renal renin expression and renal hemodynamics in response to alterations in tubular luminal chloride concentration (15). Macula densa sensing of luminal chloride is dependent on net apical transport, mediated by the luminal Na+/K+/2Cl- co-transporter, BSC-1 (28-30). Na+/K+/2Cl- co-transporter has a high affinity for Na+ and K+ but a lower affinity for Cl- (in the 30-50 mmol/l range), resulting in sensitivity to physiologic changes in luminal chloride (31). The potential role of prostaglandins in mediation of macula densa function has prompted further studies to investigate the signals mediating this increased COX-2 expression.

In our previous studies utilizing primary cultured cTALH cells, we determined that immunoreactive COX-2 expression increased significantly when medium NaCl was decreased without alterations in extracellular osmolality or following administration of the Na+/K+/2Cl- co-transport inhibitor, bumetanide. Selective substitution of chloride led to increased COX-2 expression, whereas selective substitution of sodium had no effect (16). Similarly, it has been reported recently that low chloride stimulates prostaglandin E2 release and COX-2 expression in MMDD1 cells, which are derived from mouse macula densa (32). These studies suggested that decreased extracellular [Cl-] initiates the overexpression of COX-2 observed in vivo in response to salt restriction.

The present studies indicate that a lessened extracellular chloride-mediated increase in p38 activity stimulates COX-2 expression in cTALH and macula densa by transcriptional regulation via an NF-kappa B-dependent pathway and by post-transcriptional increases in mRNA stability. In other systems, different members of the mitogen-activated protein kinase superfamily have been shown to increase COX-2 expression, including extracellular signal-regulated kinase- (33, 34), c-Jun N-terminal kinase- (34-36), and p38-dependent pathways (33-35, 37-39) (40). Our previous study indicated that activation of p38 occurred in cultured cTALH cells incubated with either low salt or low chloride medium and preceded increases in COX-2 protein expression; the increased COX-2 expression was prevented by specific p38 inhibitors (16). Similar findings were observed in MMDD1 cells (32). In addition, in vivo, increased pp38 immunoreactivity was detected in macula densa and cTALH in response to dietary sodium deprivation (16). The current study showed that p38 specific inhibitors abolished low salt-induced increase in COX-2 promoter-mediated luciferase p38 inhibition and also led to a decreased half-life of COX-2 mRNA. Therefore, the p38 pathway mediates both transcriptional and post-transcriptional regulation of COX-2 in cTALH induced by low salt/chloride.

Transcriptional regulation of COX-2 expression appears to involve diverse mechanisms in different cell types and conditions (41-46), and transcription factors, such as NF-kappa B (19, 47-50), CREB and E-box promoter elements (51), and AP-1 (52, 53), have all been determined to mediate COX-2 expression. In the present studies, the NF-kappa B inhibitor BAY 11-7082 (26) partially reversed increased luciferase activity in response to decreased NaCl or chloride, and selective deletion or mutation of a putative NF-kappa B binding site in the murine COX-2 promoter completely inhibited NaCl or chloride-mediated stimulation, suggesting a predominant role for NF-kappa B in the transcriptional regulation. EMSA confirmed stimulated nuclear NF-kappa B binding activity in response to alterations in extracellular ionic content. Furthermore, the inhibition of NF-kappa B binding activity by the p38 inhibitor SB203580 indicated that the p38 pathway mediates NF-kappa B activation.

CREB promotes recruitment of the transcriptional co-activator CBP and p300. It has been shown to function as a classic intracellular second messenger in glucose homeostasis, growth factor-dependent cell survival, and involvement in learning and memory (54). Although NF-kappa B activation appears to be absolutely necessary for low salt-mediated increases in COX-2 transcription, our luciferase activity and EMSA data also suggest the possibility of an additional role for CREB. In this regard, in activated macrophages both CREB and NF-kappa B, as well as C/EBP beta  and delta , have been identified as key factors in coordinately orchestrating COX-2 transcription (55).

NF-kappa B is a heterodimer composed of p50 and RelA/p65 subunits. Its inactive form is found in cytoplasm associated with Ikappa Balpha and Ikappa Bbeta . In response to agonist stimulation, Ikappa B is phosphorylated at two critical serine residues by Ikappa B kinase and degraded, resulting in the release of NF-kappa B, which translocates to the nucleus to activate transcription of responsive genes (56-61). Although some previous studies in other systems had not found that p38 mediated NF-kappa B nuclear translocation (62, 63), recent studies have suggested such an interaction (64, 65). In the present studies, increased levels of phosphorylated Ikappa B and decreases in level of immunoreactive Ikappa B, both of which were inhibited by p38 inhibitors, suggested that decreased medium NaCl or chloride activated Ikappa B phosphorylation in cTALH through a p38-dependent pathway.

In addition to the transcriptional induction of COX-2, stabilization of the COX-2 mRNA at the post-transcriptional level is important for maximal expression (66-68). A crucial role for AU-rich sequence elements in the COX-2 3'-untranslated region to stabilize COX-2 mRNA expression has been shown in human lung fibroblast cells (66), HeLa-To cells (68), and murine macrophage-like cells (69). Further studies will be required to determine whether p38 activation by decreased extracellular chloride increases COX-2 mRNA stability by a similar mechanism. In summary, these studies indicate that p38 stimulates COX-2 expression in cultured cTALH by transcriptional regulation predominantly via a NF-kappa B-dependent pathway and by post-transcriptional increases in mRNA stability.

    FOOTNOTES

* This work was supported by the Vanderbilt George O'Brien Kidney Satellite Research, Diseases Center with National Institutes of Health Grant DK 39261 and by funds from the Department of Veterans Affairs.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Div. of Nephrology, S3322, MCN, Vanderbilt University School of Medicine, Nashville, TN 37232. Tel.: 615-343-0030; E-mail: ray.harris@vanderbilt.edu.

Published, JBC Papers in Press, September 16, 2002, DOI 10.1074/jbc.M206040200

    ABBREVIATIONS

The abbreviations used are: COX, cyclooxygenase; cTALH, cortical thick ascending limb of Henle; EMSA, electrophoretic mobility shift assay; CREB, cAMP-response element-binding protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R., and Lefkowith, J. B. (1986) Annu. Rev. Biochem. 55, 69-102[CrossRef][Medline] [Order article via Infotrieve]
2. Masferrer, J. L., Zweifel, B. S., Seibert, K., and Needleman, P. (1990) J. Clin. Invest. 86, 1375-1379[Medline] [Order article via Infotrieve]
3. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., and Herschman, H. R. (1991) J. Biol. Chem. 266, 12866-12872[Abstract/Free Full Text]
4. O'Banion, M. K., Winn, V. D., and Young, D. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4888-4892[Abstract/Free Full Text]
5. Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N., and Breyer, M. D. (1994) J. Clin. Invest. 94, 2504-2510[Medline] [Order article via Infotrieve]
6. Jensen, B. L., and Kurtz, A. (1997) Kidney Int. 52, 1242-1249[Medline] [Order article via Infotrieve]
7. Schnermann, J. (1998) Am. J. Physiol. 274, R263-R279[Medline] [Order article via Infotrieve]
8. Cheng, H. F., Wang, J. L., Zhang, M. Z., Miyazaki, Y., Ichikawa, I., McKanna, J. A., and Harris, R. C. (1999) J. Clin. Invest. 103, 953-961[Medline] [Order article via Infotrieve]
9. Wolf, K., Castrop, H., Hartner, A., Goppelt-Strube, M., Hilgers, K. F., and Kurtz, A. (1999) Hypertension 34, 503-507[Abstract/Free Full Text]
10. Mann, B., Hartner, A., Jensen, B. L., Kammerl, M., Kramer, B. K., and Kurtz, A. (2001) Kidney Int. 59, 62-68[CrossRef][Medline] [Order article via Infotrieve]
11. Wang, J. L., Cheng, H. F., and Harris, R. C. (1999) Hypertension 34, 96-101[Abstract/Free Full Text]
12. Cheng, H. F., Wang, J. L., Zhang, M. Z., Wang, S. W., McKanna, J. A., and Harris, R. C. (2001) Am. J. Physiol. 280, F449-F456
13. Lorenz, J. N., Weihprecht, H., Schnermann, J., Skott, O., and Briggs, J. P. (1990) Am. J. Physiol. 259, F186-F193[Medline] [Order article via Infotrieve]
14. Persson, A. E., Salomonsson, M., Westerlund, P., Greger, R., Schlatter, E., and Gonzalez, E. (1991) Kidney Int. 32 (suppl.), 39-44
15. Lorenz, J. N., Weihprecht, H., Schnermann, J., Skott, O., and Briggs, J. P. (1991) Am. J. Physiol. 260, F486-F493[Medline] [Order article via Infotrieve]
16. Cheng, H. F., Wang, J. L., Zhang, M. Z., McKanna, J. A., and Harris, R. C. (2000) J. Clin. Invest. 106, 681-688[Medline] [Order article via Infotrieve]
17. Allen, M. L., Nakao, A., Sonnenburg, W. K., Burnatowska-Hledin, M., Spielman, W. S., and Smith, W. L. (1988) Am. J. Physiol. 255, F704-F710[Medline] [Order article via Infotrieve]
18. Cheng, H. F., Wang, J. L., Zhang, M. Z., McKanna, J. A., and Harris, R. C. (2000) Am. J. Physiol. 279, F122-F129
19. Yamamoto, K., Arakawa, T., Ueda, N., and Yamamoto, S. (1995) J. Biol. Chem. 270, 31315-31320[Abstract/Free Full Text]
20. Arakawa, T., Nakamura, M., Yoshimoto, T., and Yamamoto, S. (1995) FEBS Lett. 363, 105-110[CrossRef][Medline] [Order article via Infotrieve]
21. Wang, J. L., Cheng, H. F., Shappell, S., and Harris, R. C. (2000) Kidney Int. 57, 2334-2342[CrossRef][Medline] [Order article via Infotrieve]
22. Zhang, X., Huang, C. J., Nazarian, R., Ritchie, T., de Vellis, J. S., and Noble, E. P. (1997) BioTechniques 22, 848-850[Medline] [Order article via Infotrieve]
23. Sakai, T., Ichiyama, T., Whitten, C. W., Giesecke, A. H., and Lipton, J. M. (2000) Can. J. Anaesth. 47, 1019-1024[Abstract/Free Full Text]
24. Cheng, G., Hagen, T. P., Dawson, M. L., Barnes, K. V., and Menick, D. R. (1999) J. Biol. Chem. 274, 12819-12826[Abstract/Free Full Text]
25. Han, S. W., Lei, Z. M., and Rao, C. V. (1999) Mol. Cell. Endocrinol. 147, 7-16[CrossRef][Medline] [Order article via Infotrieve]
26. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., and Gerritsen, M. E. (1997) J. Biol. Chem. 272, 21096-21103[Abstract/Free Full Text]
27. Leonard, M., Ryan, M. P., Watson, A. J., Schramek, H., and Healy, E. (1999) Kidney Int. 56, 1366-1377[CrossRef][Medline] [Order article via Infotrieve]
28. Schlatter, E., Salomonsson, M., Persson, A. E., and Greger, R. (1989) Pfluegers Arch. Eur. J. Physiol. 414, 286-290[CrossRef][Medline] [Order article via Infotrieve]
29. Salomonsson, M., Gonzalez, E., Westerlund, P., and Persson, A. E. (1991) Kidney Int. 32 (suppl.), 51-54
30. Nielsen, S., Maunsbach, A. B., Ecelbarger, C. A., and Knepper, M. A. (1998) Am. J. Physiol. 275, F885-F893[Medline] [Order article via Infotrieve]
31. Greger, R. (1997) Nephrol. Dial. Transplant. 12, 2215-2217[Free Full Text]
32. Yang, T., Park, J. M., Arend, L., Huang, Y., Topaloglu, R., Pasumarthy, A., Praetorius, H., Spring, K., Briggs, J. P., and Schnermann, J. B. (2000) J. Biol. Chem. 275, 37922-37929[Abstract/Free Full Text]
33. LaPointe, M. C., and Isenovic, E. (1999) Hypertension 33, 276-282[Abstract/Free Full Text]
34. Subbaramaiah, K., Chung, W. J., and Dannenberg, A. J. (1998) J. Biol. Chem. 273, 32943-32949[Abstract/Free Full Text]
35. Guan, Z., Buckman, S. Y., Miller, B. W., Springer, L. D., and Morrison, A. R. (1998) J. Biol. Chem. 273, 28670-28676[Abstract/Free Full Text]
36. Xie, W., and Herschman, H. R. (1996) J. Biol. Chem. 271, 31742-31748[Abstract/Free Full Text]
37. Shalom-Barak, T., Quach, J., and Lotz, M. (1998) J. Biol. Chem. 273, 27467-27473[Abstract/Free Full Text]
38. Bartlett, S. R., Sawdy, R., and Mann, G. E. (1999) J. Physiol. (Lond.) 520, 399-406[Abstract/Free Full Text]
39. Ridley, S. H., Dean, J. L., Sarsfield, S. J., Brook, M., Clark, A. R., and Saklatvala, J. (1998) FEBS Lett. 439, 75-80[CrossRef][Medline] [Order article via Infotrieve]
40. Laporte, J. D., Moore, P. E., Lahiri, T., Schwartzman, I. N., Panettieri, R. A., Jr., and Shore, S. A. (2000) Am. J. Physiol. 279, L932-L941
41. Newton, R., Stevens, D. A., Hart, L. A., Lindsay, M., Adcock, I. M., and Barnes, P. J. (1997) FEBS Lett. 418, 135-138[CrossRef][Medline] [Order article via Infotrieve]
42. Wadleigh, D. J., Reddy, S. T., Kopp, E., Ghosh, S., and Herschman, H. R. (2000) J. Biol. Chem. 275, 6259-6266[Abstract/Free Full Text]
43. Reddy, S. T., Wadleigh, D. J., and Herschman, H. R. (2000) J. Biol. Chem. 275, 3107-3113[Abstract/Free Full Text]
44. Tai, H., Miyaura, C., Pilbeam, C. C., Tamura, T., Ohsugi, Y., Koishihara, Y., Kubodera, N., Kawaguchi, H., Raisz, L. G., and Suda, T. (1997) Endocrinology 138, 2372-2379[Abstract/Free Full Text]
45. Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., and Dannenberg, A. J. (1996) Cancer Res. 56, 4424-4429[Abstract/Free Full Text]
46. Slice, L. W., Bui, L., Mak, C., and Walsh, J. H. (2000) Biochem. Biophys. Res. Commun. 276, 406-410[CrossRef][Medline] [Order article via Infotrieve]
47. Lim, J. W., Kim, H., and Kim, K. H. (2001) Lab. Invest. 81, 349-360[Medline] [Order article via Infotrieve]
48. Nakao, S., Ogata, Y., Shimizu-Sasaki, E., Yamazaki, M., Furuyama, S., and Sugiya, H. (2000) Mol. Cell. Biochem. 209, 113-118[CrossRef][Medline] [Order article via Infotrieve]
49. Newton, R., Kuitert, L. M., Bergmann, M., Adcock, I. M., and Barnes, P. J. (1997) Biochem. Biophys. Res. Commun. 237, 28-32[CrossRef][Medline] [Order article via Infotrieve]
50. Iniguez, M. A., Martinez-Martinez, S., Punzon, C., Redondo, J. M., and Fresno, M. (2000) J. Biol. Chem. 275, 23627-23635[Abstract/Free Full Text]
51. Mestre, J. R., Mackrell, P. J., Rivadeneira, D. E., Stapleton, P. P., Tanabe, T., and Daly, J. M. (2001) J. Biol. Chem. 276, 3977-3982[Abstract/Free Full Text]
52. von Knethen, A., Callsen, D., and Brune, B. (1999) J. Immunol. 163, 2858-2866[Abstract/Free Full Text]
53. Subbaramaiah, K., Lin, D. T., Hart, J. C., and Dannenberg, A. J. (2001) J. Biol. Chem. 276, 12440-12448[Abstract/Free Full Text]
54. Mayr, B., and Montminy, M. (2001) Nat. Rev. Mol. Cell. Biol. 2, 599-609[CrossRef][Medline] [Order article via Infotrieve]
55. Caivano, M., Gorgoni, B., Cohen, P., and Poli, V. (2001) J. Biol. Chem. 276, 48693-48701[Abstract/Free Full Text]
56. DiDonato, J. A., Mercurio, F., and Karin, M. (1995) Mol. Cell. Biol. 15, 1302-1311[Abstract]
57. Zandi, E., and Karin, M. (1999) Mol. Cell. Biol. 19, 4547-4551[Free Full Text]
58. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. (1997) Science 278, 860-866[Abstract/Free Full Text]
59. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225-260[CrossRef][Medline] [Order article via Infotrieve]
60. Baldwin, A. S., Jr. (1996) Annu. Rev. Immunol. 14, 649-683[CrossRef][Medline] [Order article via Infotrieve]
61. Baldwin, A. S., Jr. (2001) J. Clin. Invest. 107, 3-6[CrossRef][Medline] [Order article via Infotrieve]
62. Varghese, J., Chattopadhaya, S., and Sarin, A. (2001) J. Immunol. 166, 6570-6577[Abstract/Free Full Text]
63. Goebeler, M., Gillitzer, R., Kilian, K., Utzel, K., Brocker, E. B., Rapp, U. R., and Ludwig, S. (2001) Blood 97, 46-55[Abstract/Free Full Text]
64. Schulze-Osthoff, K., Ferrari, D., Riehemann, K., and Wesselborg, S. (1997) Immunobiology 198, 35-49[Medline] [Order article via Infotrieve]
65. Ingram, A. J., James, L., Thai, K., Ly, H., Cai, L., and Scholey, J. W. (2000) Am. J. Physiol. 279, F243-F251
66. Jang, B. C., Sanchez, T., Schaefers, H. J., Trifan, O. C., Liu, C. H., Creminon, C., Huang, C. K., and Hla, T. (2000) J. Biol. Chem. 275, 39507-39515[Abstract/Free Full Text]
67. Ristimaki, A., Narko, K., and Hla, T. (1996) Biochem. J. 318, 325-331[Medline] [Order article via Infotrieve]
68. Lasa, M., Mahtani, K. R., Finch, A., Brewer, G., Saklatvala, J., and Clark, A. R. (2000) Mol. Cell. Biol. 20, 4265-4274[Abstract/Free Full Text]
69. Dean, J. L., Wait, R., Mahtani, K. R., Sully, G., Clark, A. R., and Saklatvala, J. (2001) Mol. Cell. Biol. 21, 721-730[Abstract/Free Full Text]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
F. Hanner, R. Chambrey, S. Bourgeois, E. Meer, I. Mucsi, L. Rosivall, G. E. Shull, J. N. Lorenz, D. Eladari, and J. Peti-Peterdi
Increased renal renin content in mice lacking the Na+/H+ exchanger NHE2
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F937 - F944.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Xu and H.-K. G. Shu
EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase-Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas
Cancer Res., July 1, 2007; 67(13): 6121 - 6129.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M.-Z. Zhang, B. Yao, H.-F. Cheng, S.-W. Wang, T. Inagami, and R. C. Harris
Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT1 and AT2 receptors
PNAS, October 24, 2006; 103(43): 16045 - 16050.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
H.-F. Cheng, M.-Z. Zhang, and R. C. Harris
Nitric oxide stimulates cyclooxygenase-2 in cultured cTAL cells through a p38-dependent pathway
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1391 - F1397.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. C. Harris and M. D. Breyer
Update on Cyclooxygenase-2 Inhibitors
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. V. Grishin, J. Wang, D. A. Potoka, D. J. Hackam, J. S. Upperman, P. Boyle, R. Zamora, and H. R. Ford
Lipopolysaccharide Induces Cyclooxygenase-2 in Intestinal Epithelium via a Noncanonical p38 MAPK Pathway
J. Immunol., January 1, 2006; 176(1): 580 - 588.
[Abstract] [Full Text] [PDF]